| Epilepsies in children, young people and adults | QS211 | | |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
| Risdiplam for treating spinal muscular atrophy | TA755 | | |
| Digitally enabled therapies for adults with anxiety disorders: early value assessment | HTE9 | | |
| Middle meningeal artery embolisation for chronic subdural haematomas | IPG779 | | |
| Cardiovascular disease: risk assessment and reduction, including lipid modification | NG238 | | |
| Transition from children's to adults' services | QS140 | | |
| Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
| Velmanase alfa for treating alpha-mannosidosis | HST29 | | |
| Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | | |
| Acne vulgaris: management | NG198 | | |
| Secukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | | |
| Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | | |
| Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | | |
| Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | | |
| Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism | IPG778 | | |
| Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | | |
| Zanubrutinib for treating chronic lymphocytic leukaemia | TA931 | | |
| Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis | IPG777 | | |
| Transient loss of consciousness ('blackouts') in over 16s | CG109 | | |
| Hypertension in adults: diagnosis and management | NG136 | | |
| Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management | NG237 | | |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
| Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment | HTE15 | | |
| Biodegradable subacromial spacer insertion for rotator cuff tears | IPG775 | | |
| Extracorporeal carbon dioxide removal for acute respiratory failure | IPG776 | | |
| Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | CG164 | | |
| Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | | |
| Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
| Jaundice in newborn babies under 28 days | CG98 | | |
| Pneumonia in adults: diagnosis and management | CG191 | | |
| Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) | QS210 | | |
| Ranibizumab for treating diabetic macular oedema | TA274 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA917 | | |
| Tirzepatide for treating type 2 diabetes | TA924 | | |
| Baricitinib for treating severe alopecia areata | TA926 | | |
| Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions | IPG774 | | |
| Mirikizumab for treating moderately to severely active ulcerative colitis | TA925 | | |
| Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) | TA923 | | |
| Rimegepant for treating migraine | TA919 | | |
| Tofacitinib for treating active ankylosing spondylitis | TA920 | | |
| Ruxolitinib for treating polycythaemia vera | TA921 | | |
| Daridorexant for treating long-term insomnia | TA922 | | |
| Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia | IPG773 | | |
| Stroke rehabilitation in adults | NG236 | | |
| Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
| Thyroid disease: assessment and management | NG145 | | |
| Virtual ward platform technologies for acute respiratory infections: early value assessment | HTE13 | | |
| Bimekizumab for treating axial spondyloarthritis | TA918 | | |
| Pegunigalsidase alfa for treating Fabry disease | TA915 | | |